| Trial ID: | L6366 |
| Source ID: | NCT01366287
|
| Associated Drug: |
Pf-03882845
|
| Title: |
A Study Of PF-03882845 Absorption In Healthy Volunteers Given Orally As Tablet Versus Suspension Formulations And Effect Of Food On Its Absorption
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: PF-03882845|DRUG: PF-03882845|DRUG: PF-03882845
|
| Outcome Measures: |
Primary: PF-03882845 PK: Cmax, AUCinf, AUClast, Tmax, t1/2, as data permit., Post dose is measured at 24, 48 and 96 hours after dose., predose and post each dose (24, 48 and 96 hour timepoints)|Safety: Safety labs, vital signs, ECGs, physical examinations and adverse event monitoring., 45 days |
|
| Sponsor/Collaborators: |
Sponsor: Pfizer
|
| Gender: |
ALL
|
| Age: |
ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
12
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: BASIC_SCIENCE
|
| Start Date: |
2011-01
|
| Completion Date: |
2011-02
|
| Results First Posted: |
|
| Last Update Posted: |
2011-06-06
|
| Locations: |
Pfizer Investigational Site, Bruxelles, 1070, Belgium
|
| URL: |
https://clinicaltrials.gov/show/NCT01366287
|
